Premium
Issues encountered in recent attempts to develop novel antidepressant agents
Author(s) -
Schatzberg Alan F.
Publication year - 2015
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12716
Subject(s) - monoaminergic , antidepressant , neuroscience , drug development , deep brain stimulation , psychology , medicine , pharmacology , drug , serotonin , receptor , hippocampus , disease , parkinson's disease
The development of new antidepressants has had mixed results over the past decade, with several notable failures. This paper reviews a number of major initiatives in the development of new antidepressant agents. Traditional strategies to build on agents that have monoaminergic effects at the synapse (e.g., vilazodone and ketamine) have been complemented with efforts that have emphasized devices and brain circuits (e.g., deep brain stimulation and transcranial magnetic stimulation) or chemical agents that modulate neuroendocrine systems (e.g., glucocorticoid antagonists, mixed melatonin agonists/serotonin type‐2 receptor antagonists). Interestingly, chemical agents, such as onabotulinumtoxin A, may affect brain circuits as well. We present data from recent studies in drug and device development—reviewing progress made, stumbling blocks encountered, and issues that need to be addressed in future studies.